The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...

Virginia facility investment will be AstraZeneca’s largest yet. Maryland, Massachusetts, California, Indiana, Texas projects ...

AstraZeneca announces $50B US investment by 2030, creating thousands of jobs and building its largest drug manufacturing facility in Virginia.

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

Research news of note last week included US biotech Crinetics Pharmaceuticals releasing new Phase III data on its acromegaly drug candidate Palsonify (paltusotine). AstraZeneca announced positive ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

A promising new drug may finally bring hope to people suffering from a common but often overlooked cause of high blood ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...